ORMP
HEALTHCAREOramed Pharmaceuticals Inc
$3.92-0.06 (-1.51%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ORMP Today?
No stock-specific AI insight has been generated for ORMP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.85$4.22
$3.92
Fundamentals
Market Cap$158M
P/E Ratio2.6
EPS$1.50
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin32.0%
Debt / Equity—
Trading
Volume136K
Avg Volume (10D)—
Shares Outstanding40.4M
ORMP News
20 articles- Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy InvestorsYahoo Finance·Apr 14, 2026
- Oramed: Q4 Earnings SnapshotYahoo Finance·Mar 26, 2026
- Lifeward Successfully Closes on Strategic Partnership with OramedYahoo Finance·Mar 25, 2026
- Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyYahoo Finance·Mar 13, 2026
- ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder ValueYahoo Finance·Feb 26, 2026
- CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a TurnaroundMotley Fool·Feb 3, 2026
- Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.Motley Fool·Feb 3, 2026
- 3 Promising Penny Stocks With Market Caps Under $200MYahoo Finance·Jan 14, 2026
- Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation CompanyYahoo Finance·Jan 13, 2026
- Oramed and Lifeward Announce Strategic TransactionYahoo Finance·Jan 13, 2026
- Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsYahoo Finance·Jan 7, 2026
- Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To WatchYahoo Finance·Dec 16, 2025
- ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan AdoptedYahoo Finance·Nov 24, 2025
- There Are Some Holes In Oramed Pharmaceuticals' (NASDAQ:ORMP) Solid Earnings ReleaseYahoo Finance·Nov 21, 2025
- Oramed Reports Fiscal Third Quarter 2025 Financial ResultsYahoo Finance·Nov 17, 2025
- ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTSYahoo Finance·Nov 17, 2025
- Oramed: Q3 Earnings SnapshotYahoo Finance·Nov 13, 2025
- The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableYahoo Finance·Oct 28, 2025
- Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth InitiativesYahoo Finance·Oct 23, 2025
- Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant RepurchaseYahoo Finance·Oct 1, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$3.98
Day High$0.00
Day Low$0.00
52 Week High$4.22
52 Week Low$1.85
52-Week Range
$1.85$4.22
$3.92
Fundamentals
Market Cap$158M
P/E Ratio2.6
EPS$1.50
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin32.0%
Debt / Equity—
Trading
Volume136K
Avg Volume (10D)—
Shares Outstanding40.4M
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—